Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis
Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres
BACKGROUND: Anti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC). While some patients with NSCLC have pre-existing interstitial lung disease (ILD), data on the long-term safety and effectiveness of …
jp (code pays fourni par la source)
0 citations
BMC Cancer